President and CEO of Novavax Inc (NVAX, Financial) Stanley C Erck bought 100,000 shares of NVAX on 11/09/2017 at an average price of $1.13 a share. The total cost of this purchase was $113,000.
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. Novavax Inc has a market cap of $354.390 million; its shares were traded at around $1.13 with and P/S ratio of 14.68. Novavax Inc had annual average EBITDA growth of 3.00% over the past ten years.
CEO Recent Trades:
- President and CEO Stanley C Erck bought 100,000 shares of NVAX stock on 11/09/2017 at the average price of $1.13. The price of the stock has decreased by 0% since.
Directors and Officers Recent Trades:
- President, R&D Gregory M Glenn bought 10,000 shares of NVAX stock on 11/09/2017 at the average price of $1.13. The price of the stock has decreased by 0% since.
For the complete insider trading history of NVAX, click here
.